6533b820fe1ef96bd1279a54
RESEARCH PRODUCT
Studies on the Intravesical Action of Topically Administered G 3 H-Doxorubicin Hydrochloride in Men: Plasma Uptake and Tumor Penetration
Karl-heinz KurthGünther H. Jacobisubject
MaleDrugmedicine.medical_specialtyPathologyHydrochlorideAdministration TopicalUrologymedia_common.quotation_subjectUrinary systemmedicine.medical_treatmentUrinary BladderUrologychemistry.chemical_compoundHumansMedicineUrotheliumSalinemedia_commonCarcinoma Transitional Cellbusiness.industryPapillary tumorMiddle Agedmedicine.diseaseTransitional cell carcinomaUrinary Bladder NeoplasmschemistryDoxorubicinDoxorubicin HydrochlorideNeoplasm Recurrence Localbusinessdescription
AbstractDoxorubicin hydrochloride has been used for the treatment and prevention of recurrences of transitional cell carcinoma. Ideal indications for the drug and side effects have not been determined. In this regard the penetration of the drug into the bladder wall and the urothelium as a urinary blood barrier is of interest. Using a tritium label we have investigated tumor penetration and transmucosal plasma uptake of doxorubicin hydrochloride after intravesical application in 7 patients with stage A bladder tumors. Of the 7 patients 5 were free of tumor following transurethral resection and 2 had recurrent disease. The patients free of tumor received 40mg. doxorubicin hydrochloride per 30ml. normal saline with 1.2mg. G3H-doxorubicin hydrochloride (27.8mCi./mMol.) intravesically for 2hours. Blood was drawn for up to 120 minutes and plasma was assayed for radioactivity. The patients with recurrent papillary tumor received 2.3mg. labeled doxorubicin hydrochloride along with 40mg. cold substance and underw...
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1980-07-01 | Journal of Urology |